The NHS Accelerated Access Collaborative (AAC) Rapid Uptake Products (RUP) Asthma Biologics programme has produced a set of three patient information leaflets to support better care for adults with severe and uncontrolled asthma.
Download leaflets 📄 https://t.co/f1nqiTsfgj
"People who vandalise public spaces will have to repair the damage they cause within 48 hours of being given an order."
Great news! Looking forward to the head of Southern Water having to put on a hi-vis jacket and clean up the shit that's been dumped on our beaches... #YeahRight
📣 Congratulations to Newcastle Physiotherapist @paul_mccallion whose @NIHRcommunity’s Doctoral Clinical Academic Fellowship will support his research into bronchiectasis aiming to greatly improve patient experience, QoL & long-term health outcomes 👏👏
https://t.co/F7PdkGK3aS
ERJOR: A scoping review demonstrates bronchiectasis multimorbidity is common, and associated with increased mortality, exacerbations and hospitalisation. It negatively impacts lung function. There is a deficit of research in key areas, such as management. https://t.co/8EQirZl4pk
Seconday care staff. Did you know that anyone with an https://t.co/Gx5sc2vjAA email can use @Accurx to send texts to patients?
I use it all the time to send patient information leaflets and links to videos and support groups, especially when doing phone clinics.
@MichaelScottRN@KarenMarshall02@cf_newcastle As a general rule 20% drop (or 15% with symptoms) would preclude nebulised. A starting FEV1 <30% would also be a significant barrier. As ever there would be wriggle room if limited other issues e.g. intolerance to cipro